Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wellbeing Digital Sciences Inc (OP: KONEF )

0.0080 UNCHANGED
Streaming Delayed Price Updated: 3:53 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50
Open 0.0080
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0080
Today's Range 0.0080 - 0.0080
52wk Range 0.0036 - 0.4400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire

Performance

YTD
+81.82%
+81.82%
1 Month
+8.11%
+8.11%
3 Month
+50.94%
+50.94%
6 Month
-79.43%
-79.43%
1 Year
-94.75%
-94.75%

More News

Read More
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Via Benzinga
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
From Wellbeing Digital Sciences Inc.
Via Business Wire
Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
Via Benzinga
Wellbeing Digital to Participate in The Global Biomedical Design Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
Via Benzinga
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
From WELLBEING DIGITAL SCIENCES
Via Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
From Wellbeing Digital Sciences Inc.
Via Business Wire
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Via Benzinga
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order
From Wellbeing Digital Sciences Inc.
Via Business Wire
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
Via Benzinga
Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Announces Change of Auditor
From Wellbeing Digital Sciences Inc.
Via Business Wire
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
Via Benzinga
Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Via Benzinga
Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.